All the news Showing 10 of 86 articles from: Treatment for people living with HIV and HCVGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir/ledipasvir for 8 weeks cures most hard-to-treat hepatitis C patients in real-world study Liz Highleyman / 10 November 2015 Most people with hepatitis C virus (HCV) in the GECCO German hepatitis C cohort who were treated with sofosbuvir/ledipasvir (Harvoni) for 8 weeks in a real-world clinical setting achieved sustained virological response, even those ... Successful hepatitis C treatment lowers risk of death for people with HIV and HCV co-infection Liz Highleyman / 09 November 2015 Hepatitis C treatment that leads to sustained virological response (SVR) – generally regarded as a cure – was associated with a reduced risk of liver-related death and improved overall survival in an analysis ... New HCV NS5A inhibitor EDP-239 looks good in early studies, more evidence supports early hepatitis C treatment Keith Alcorn / 07 October 2015 A new hepatitis C virus (HCV) NS5A inhibitor being developed by Enanta – EDP-239 – was well-tolerated and demonstrated promising antiviral activity against genotype 1 HCV in a single-dose monotherapy study presented at ... Interferon-free hepatitis treatment is highly effective for people with HIV and HCV co-infection in three studies Liz Highleyman / 10 August 2015 Three different interferon-free regimens – sofosbuvir/ledipasvir, AbbVie's 3D regimen and grazoprevir/elbasvir – were well-tolerated and cured more than 90% of participants with HIV and HCV co-infection in three clinical trials, confirming that HIV-positive ... Liver fibrosis regression after hepatitis C treatment linked to reduced complications and death in people with HIV and HCV co-infection Liz Highleyman / 06 August 2015 People with HIV and HCV co-infection, with liver cirrhosis, who achieve sustained virological response (SVR) and experience an improvement in liver fibrosis are less likely to develop liver disease complications or die from ... Daclatasvir plus sofosbuvir cures HCV for most people with HIV and HCV co-infection in French compassionate use programme Liz Highleyman / 05 August 2015 Interferon-free treatment using daclatasvir (Daklinza) and sofosbuvir (Sovaldi), with or without ribavirin, was well-tolerated and produced sustained virological response rates of 95-100% for people with HIV and HCV co-infection and advanced liver disease, ... Access to screening and treatment are key issues for hepatitis B and C and HIV/viral hepatitis co-infection Liz Highleyman / 04 August 2015 The development of effective new interferon-free treatment makes it possible to cure more than 90% of people with chronic hepatitis C, including most people with HIV and hepatitis C virus (HCV) co-infection, researchers ... Liver transplants in HIV/HCV co-infection: study underlines importance of hepatitis C treatment Keith Alcorn / 29 June 2015 People with HIV and hepatitis C co-infection were significantly more likely to experience organ rejection than people with hepatitis C alone or HIV alone after undergoing a liver transplant, according to a ... Sofosbuvir plus daclatasvir for 12 weeks cures HCV for most people with HIV/HCV co-infection Liz Highleyman / 04 June 2015 Nearly all trial participants with HIV and hepatitis C virus (HCV) co-infection, who were treated for 12 weeks with an interferon- and ribavirin-free regimen of sofosbuvir (Sovaldi) and daclatasvir (Daklinza), achieved ... Grazoprevir/elbasvir highly effective in treatment-experienced and HIV-coinfected hepatitis C patients Keith Alcorn / 25 April 2015 The combination of grazoprevir and elbasvir without ribavirin is highly effective in curing hepatitis C infection in 12 weeks in some groups of treatment-experienced patients and in people with HIV co-infection, and a ... ← Prev1...34567...9Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive